The AAMC joined other national hospital associations and the American Society of Health-System Pharmacists in a Sept. 9 letter to the Centers for Medicare & Medicaid Services (CMS) (PDF) on its proposed implementation of the Inflation Reduction Act (IRA) (P.L. 117-169). In the 2025 Physician Fee Schedule (PFS) and Quality Payment Program (QPP) proposed rule [refer to Washington Highlights, July 12], the CMS proposed an estimation methodology for excluding units of drugs purchased through the 340B Drug Pricing Program from Part D inflationary rebates mandated by the IRA. In the letter, the AAMC and other associations applauded the CMS for not requiring the use of 340B claim identifiers and supported the use of the estimation methodology. The letter also urged the CMS to ensure that if it were to instead use a retrospective claims repository to identify 340B drug units, 340B claims data not be shared with drug manufacturers. The AAMC included similar comments on the IRA provisions in its individual CY 2025 PFS and QPP proposed rule comment letter [refer to related story]
- Washington Highlights